SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Summit Therapeutics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026

$15.57+0.94 (+6.43%)

Close on Oct 19, 2026

Market cap: $12.12B
P/E (TTM): –
Dividend yield: –

Summit Therapeutics Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2019 2019-01-31
Stock-Based Compensation	732	51	14	12	13	6.30
Deferred Income Taxes	–	–	–	–	0	-1.91
Other Non-Cash Items	–	–	–	0.00	-0.30	0
Change in Accounts Receivable	–	0	0.36	0.98	-1.14	-2.47
Change in Accounts Payable	15	2.02	2.26	-4.13	-1.71	-0.01
Change in Unearned Revenue	–	0	0	-7.28	-0.81	-49
Operating Cash Flow	-323	-142	-77	-42	-73	-35
Capital Expenditures	-0.66	-0.14	-0.13	-0.62	-0.31	-0.16
Sale of Property, Plant & Equipment	0	0	0.23	0	–	–
Purchase of Investments	-485	-680	-321	0	–	–
Investing Cash Flow	-174	-205	-588	-0.62	-0.31	-0.33
Dividends Paid	–	–	–	–	–	0
Stock Issued	–	–	105	100	75	46
Financing Cash Flow	618	381	87	620	78	45
Foreign Exchange Rate Adjustments	0.10	-0.02	0.84	-1.22	0.35	-2.32
Net Change in Cash	120	34	-577	577	5.37	6.75
Free Cash Flow	-324	-142	-77	-42	-73	-35
Income Taxes Paid	0	0	0.05	0	0.01	0.07
Interest Paid	0	8.81	11	0.43	0.09	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -206.1%

Financial strength

Current ratio: 6.96
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 404.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 19.23
Dividend yield: –